Cargando…
Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis
Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ~1.74 million deaths annually. Current therapy consists of multiple antibiotics and a lengthy treatment regimen, which is associated with risk for the generation of drug-resis...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409628/ https://www.ncbi.nlm.nih.gov/pubmed/34415976 http://dx.doi.org/10.1371/journal.ppat.1009805 |